Cover Image
Market Research Report

Global Immunosuppressant Drugs Market Forecast 2019-2028

Published by Inkwood Research Product code 939709
Published Content info 135 Pages
Delivery time: 2-3 business days
Price
Back to Top
Global Immunosuppressant Drugs Market Forecast 2019-2028
Published: June 1, 2020 Content info: 135 Pages
Description

KEY FINDINGS

The global immunosuppressant drugs market is projected to register growth at a CAGR of 4.17% during the projected period, 2019-2028. The growing incidences of autoimmune disorders, the growing pharmaceutical industry, and the increase in organ transplantation, are the major factors fueling the market growth.

MARKET INSIGHTS

Organ transplantation has been on the rise across the globe. This is because of the prevalence of genetic conditions like cystic fibrosis, heart defect, and polycystic kidney disease. Infections like hepatitis, damage to organs due to chronic conditions like diabetes, physical injuries, are other factors that are responsible for an organ transplant. Immunosuppressive drugs come into the scene post organ transplantation, while combatting the hyper-immune response of the patient's immune system. Thus, the growing demand for organ transplantation procedures is estimated to have a major impact on the growth of the market. Though immunosuppressive drugs have improved the outcome of organ transplantation, the side effects of such drugs can be serious, and this is one of the major factors hindering the market growth.

REGIONAL INSIGHTS

The global immunosuppressant drugs market is geographically analyzed through the regions of Europe, North America, Asia Pacific, and the rest of the world. The North America region garnered the largest market share, while the Asia Pacific region is slated to record the highest growth rate by the end of the forecast period. The government funding, prevailing auto-immune diseases, and increasing demands for organ transplantation, contribute to the market prospects of North America.

COMPETITIVE INSIGHTS

The competitive environment of the market is evaluated to be stiff, given the workings of the pharmaceutical business. Some of the leading companies in the market are Allergan Plc (Acquired By AbbVie Inc), Bristol-Myers Squibb Company, Cipla Ltd, AbbVie Inc, Astellas Pharma Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 31808

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. INCREASE IN THE NUMBER OF AUTOIMMUNE DISORDERS
    • 3.3.2. RISE IN ORGAN TRANSPLANTATION
    • 3.3.3. GROWTH IN THE PHARMACEUTICAL INDUSTRY
  • 3.4. KEY RESTRAINTS
    • 3.4.1. SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
    • 3.4.2. LACK OF AWARENESS ABOUT ORGAN DONATION

4. KEY ANALYTICS

  • 4.1. KEY INVESTMENT INSIGHTS
  • 4.2. PORTER'S FIVE FORCE ANALYSIS
    • 4.2.1. BUYER POWER
    • 4.2.2. SUPPLIER POWER
    • 4.2.3. SUBSTITUTION
    • 4.2.4. NEW ENTRANTS
    • 4.2.5. INDUSTRY RIVALRY
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE

5. MARKET BY DISTRIBUTION CHANNEL

  • 5.1. HOSPITAL PHARMACIES
  • 5.2. RETAIL PHARMACIES
  • 5.3. ONLINE PHARMACIES

6. MARKET BY END-USER

  • 6.1. ORGAN TRANSPLANTATION
  • 6.2. AUTOIMMUNE DISORDERS
  • 6.3. OTHERS

7. MARKET BY DRUG CLASS

  • 7.1. CORTICOSTEROIDS
  • 7.2. MONOCLONAL ANTIBODIES
  • 7.3. CALCINEURIN INHIBITORS
  • 7.4. MTOR INHIBITORS
  • 7.5. OTHERS

8. GEOGRAPHICAL ANALYSIS

  • 8.1. NORTH AMERICA
    • 8.1.1. UNITED STATES
    • 8.1.2. CANADA
  • 8.2. EUROPE
    • 8.2.1. UNITED KINGDOM
    • 8.2.2. GERMANY
    • 8.2.3. FRANCE
    • 8.2.4. ITALY
    • 8.2.5. RUSSIA
    • 8.2.6. BELGIUM
    • 8.2.7. POLAND
    • 8.2.8. REST OF EUROPE
  • 8.3. ASIA PACIFIC
    • 8.3.1. CHINA
    • 8.3.2. JAPAN
    • 8.3.3. INDIA
    • 8.3.4. SOUTH KOREA
    • 8.3.5. INDONESIA
    • 8.3.6. THAILAND
    • 8.3.7. VIETNAM
    • 8.3.8. AUSTRALIA & NEW ZEALAND
    • 8.3.9. REST OF ASIA PACIFIC
  • 8.4. REST OF WORLD
    • 8.4.1. LATIN AMERICA
    • 8.4.2. MIDDLE EAST & AFRICA

9. COMPANY PROFILES

  • 9.1. ABBVIE INC
  • 9.2. ALLERGAN PLC (ACQUIRED BY ABVIE INC)
  • 9.3. ASTELLAS PHARMA INC
  • 9.4. BRISTOL-MYERS SQUIBB COMPANY
  • 9.5. CIPLA LTD
  • 9.6. DR. REDDY'S LABORATORIES LTD
  • 9.7. F HOFFMANN-LA ROCHE AG
  • 9.8. GLAXOSMITHKLINE PLC
  • 9.9. INTAS PHARMACEUTICALS LTD (ACCORD HEALTHCARE LTD)
  • 9.10. JANSSEN PHARMACEUTICALS NV (JHONSON & JHONSON)
  • 9.11. MYLAN NV
  • 9.12. NOVARTIS INTERNATIONAL AG (SANDOZ)
  • 9.13. PFIZER INC
  • 9.14. SANOFI SA
  • 9.15. VELOXIS PHARMACEUTICALS

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - IMMUNOSUPPRESSANT DRUGS
  • TABLE 2: SIDE EFFECTS OF IMMUNOSUPPRESSANT DRUGS
  • TABLE 3: TOP 15 POSITIVE NET EXPORTS COUNTRIES AND NEGATIVE NET EXPORTS FOR DRUGS & MEDICINES COUNTRIES
  • TABLE 4: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL RETAIL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL RETAIL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL ONLINE PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL ORGAN TRANSPLANTATION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL ORGAN TRANSPLANTATION MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL AUTOIMMUNE DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL AUTOIMMUNE DISORDERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL CORTICOSTEROIDS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL CORTICOSTEROIDS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL CALCINEURIN INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL CALCINEURIN INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL MTOR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL MTOR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 34: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 36: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 38: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 40: REST OF WORLD IMMUNOSUPPRESSANT DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: REST OF WORLD IMMUNOSUPPRESSANT DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: DEVELOPMENT OF IMMUNOSUPPRESSANT DRUGS
  • FIGURE 2: KEY INVESTMENT INSIGHTS
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2019
  • FIGURE 7: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY ONLINE PHARMACIES, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2019
  • FIGURE 11: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY ORGAN TRANSPLANTATION, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY AUTOIMMUNE DISORDERS, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, GROWTH POTENTIAL, BY CLASS, IN 2019
  • FIGURE 15: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CORTICOSTEROIDS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY CALCINEURIN INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: NORTH AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 21: UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 22: CANADA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 23: EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 24: UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 25: GERMANY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: FRANCE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: ITALY IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 28: RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: BELGIUM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 30: POLAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: REST OF EUROPE IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 33: CHINA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: JAPAN IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: INDIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 37: INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 38: THAILAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 39: VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 40: AUSTRALIA & NEW ZEALAND IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 41: REST OF ASIA PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION
  • FIGURE 42: REST OF WORLD IMMUNOSUPPRESSANT DRUGS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 43: LATIN AMERICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 44: MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET, 2019-2028 (IN $ MILLION)
Back to Top